Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 4, 2013, Pages 527-541

  Duarte, A I ^a   Candeias, E ^a   Correia, S C ^a,b   Santos, R X ^a,b   Carvalho, C ^a,b   Cardoso, S ^a,b   Placido A ^a,c   Santos, M S ^a,b   Oliveira, C R ^a,c   Moreira, P I ^a,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Alzheimer's disease; Brain; Diabetes; Glucagon like peptide 1 mimetics; Insulin signaling; Neuroprotection

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 AMINOBUTYRIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN RECEPTOR; LEPTIN; LIRAGLUTIDE; NEUROPEPTIDE Y; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL LYASE; PIOGLITAZONE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SITAGLIPTIN; SOMATOMEDIN C;

ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; BLOOD BRAIN BARRIER; BRAIN; CEREBROSPINAL FLUID; DIARRHEA; FOOD INTAKE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HIPPOCAMPUS; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TREATMENT; MITOCHONDRION; NAUSEA; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYNAPSE;

ALZHEIMER DISEASE; BIOMIMETICS; BRAIN; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INSULIN RESISTANCE; PEPTIDES; VENOMS;

EID: 84873306844     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.01.008     Document Type: Review

References (305)

1. Duarte A.I., Moreira P.I., Oliveira C.R. Insulin in central nervous system: more than just a peripheral hormone. J. Aging Res. 2012, 384017-384038.
2. Campbell R.K. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin. Ther. 2011, 33:511-527.
3. Sicree R., Shaw J., Zimmet P. Diabetes Atlas 2006, 15-103. International Diabetes Federation, Brussels. third ed. D. Gan (Ed.).
4. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
5. International Diabetes Federation, Diabetes Atlas: Diabetes and impaired glucose tolerance. Global burden: prevalence and projections, 2010 and 2030 (Accessed August 2nd, 2012). http://www.idf.org/diabetesatlas/5e/the-global-burden.
6. World Health Organization Diabetes facts, fact sheet no. 312 (accessed August 2nd, 2012). http://www.who.int/mediacentre/factsheets/fs312/en/.
7. Carvalho C., Cardoso S., Correia S.C., Santos R.X., Santos M.S., Baldeiras I., Oliveira C.R., Moreira P.I. Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities. Diabetes 2012, 61:1234-1242.
8. Luchsinger J.A., Reitz C., Patel B., Tang M.X., Manly J.J., Mayeux R. Relation of diabetes to mild cognitive impairment. Arch. Neurol. 2007, 64:570-575.
9. Li L., Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev. 2007, 56:384-402.
10. Biessels G.J., Gispen W.H. The impact of diabetes on cognition: what can be learned from rodent models?. Neurobiol. Aging 2005, 26:S36-S41.
11. Moreira P.I., Duarte A.I., Santos M.S., Rego A.C., Oliveira C.R. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J. Alzheimers Dis. 2009, 16:741-761.
12. Magierski R., Kłoszewska I., Sobów T.M. The influence of vascular risk factors on the survival rate of patients with dementia with Lewy bodies and Alzheimer disease. Neurol. Neurochir. Pol. 2010, 44:139-147.
13. Akisaki T., Sakurai T., Takata T., Umegaki H., Araki A., Mizuno S., Tanaka S., Ohashi Y., Iguchi A., Yokono K., Ito H. Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab. Res. Rev. 2006, 22:376-384.
14. den Heijer T., Vermeer S.E., van Dijk E.J., Prins N.D., Koudstaal P.J., Hofman A., Breteler M.M. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003, 46:1604-1610.
15. Manschot S.M., Brands A.M., van der Grond J., Kessels R.P., Algra A., Kappelle L.J., Biessels G.J. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 2006, 55:1106-1113.
16. Schmidt R., Launer L.J., Nilsson L.G., Pajak A., Sans S., Berger K., Breteler M.M., de Ridder M., Dufouil C., Fuhrer R., Giampaoli S., Hofman A. Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes 2004, 53:687-692.
17. Toth C., Schmidt A.M., Tuor U.I., Francis G., Foniok T., Brussee V., Kaur J., Yan S.F., Martinez J.A., Barber P.A., Buchan A., Zochodne D.W. Diabetes, leukoencephalopathy and rage. Neurobiol. Dis. 2006, 23:445-461.
18. Correia S.C., Santos R.X., Carvalho C., Cardoso S., Candeias E., Santos M.S., Oliveira C.R., Moreira P.I. Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. Brain Res. 2012, 1441:64-78.
19. Roriz-Filho J.S., Sa-Roriz T.M., Rosset I., Camozzato A.L., Santos A.C., Chaves M.L., Moriguti J.C., Roriz-Cruz M. (Pre)diabetes, brain aging, and cognition. Biochim. Biophys. Acta 2009, 1792:432-443.
20. Bruehl H., Wolf O.T., Sweat V., Tirsi A., Richardson S., Convit A. Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. Brain Res. 2009, 1280:186-194.
21. Salkovic-Petrisic M., Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J. Neural Transm. 2007, 72:217-233.
22. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 2005, 26(Suppl.):S65-S69.
23. Laron Z. Insulin and the brain. Arch. Physiol. Biochem. 2009, 115:112-116.
24. Erol A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. J. Alzheimers Dis. 2008, 13:241-253.
25. Schechter R., Whitmire J., Holtzclaw L., George M., Harlow R., Devaskar S.U. Developmental regulation of insulin in the mammalian central nervous system. Brain Res. 1992, 582:27-37.
26. LeRoith D. CNS regulation of carbohydrate metabolism. Advances in Metabolic Disorders 1983, vol. 10:304-340. Academic Press. A. Szabo (Ed.).
27. Schulingkamp R.J., Pagano T.C., Hung D., Raffa R.B. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci. Biobehav. Rev. 2000, 24:855-872.
28. Watson G.S., Peskind E.R., Asthana S., Purganan K., Wait C., Chapman D., Schwartz M.W., Plymate S., Craft S. Insulin increases CSF Abeta42 levels in normal older adults. Neurology 2003, 60:1899-1903.
29. Hoyer S. Memory function and brain glucose metabolism. Pharmacopsychiatry 2003, 36:S62-S67.
30. Piroli G.G., Grillo C.A., Charron M.J., McEwen B.S., Reagan L.P. Biphasic effects of stress upon GLUT8 glucose transporter expression and trafficking in the diabetic rat hippocampus. Brain Res. 2004, 1006:28-35.
31. Brands A.M., Biessels G.J., de Haan E.H., Kappelle L.J., Kessels R.P. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 2005, 28:726-735.
32. Freude S., Plum L., Schnitker J., Leeser U., Udelhoven M., Krone W., Bruning J.C., Schubert M. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 2005, 54:3343-3348.
33. Biessels G.J., Kamal A., Urban I.J., Spruijt B.M., Erkelens D.W., Gispen W.H. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res. 1998, 800:125-135.
34. Li Z.G., Zhang W., Grunberger G., Sima A.A. Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res. 2002, 946:221-231.
35. Sima A.A., Li Z.G. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats. Diabetes 2005, 54:1497-1505.
36. Li Z.G., Zhang W., Sima A.A. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007, 56:1817-1824.
37. Sankar R., Thamotharan S., Shin D., Moley K.H., Devaskar S.U. Insulin-responsive glucose transporters-GLUT8 and GLUT4 are expressed in the developing mammalian brain. Mol. Brain Res. 2002, 107:157-165.
38. Porte D., Seeley R.J., Woods S.C., Baskin D.G., Figlewicz D.P., Schwartz M.W. Obesity, diabetes and the central nervous system. Diabetologia 1998, 41:863-881.
39. Clarke D.W., Mudd L., Boyd F.T. Insulin is released from rat brain neuronal cells in culture. J. Neurochem. 1986, 47:831-836.
40. Havrankova J., Roth J., Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978, 272:827-829.
41. Levin B.E. Factors promoting and ameliorating the development of obesity. Physiol. Behav. 2005, 86:633-639.
42. Sievenpiper J.L., Jenkins A.L., Whitham D.L., Vuksan V. Insulin resistance: concepts, controversies, and the role of nutrition. Can. J. Diet. Pract. Res. 2002, 63:20-32.
43. Metabolic sensing neurons and the control of energy homeostasis. Physiol. Behav. 2006, 89:486-489.
44. Porte D., Baskin D.G., Schwartz M.W. Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005, 54:1264-1276.
45. Levin B.E., Routh V.H., Kang L., Sanders N.M., Dunn-Meynell A.A. Neuronal glucosensing: what do we know after 50years?. Diabetes 2004, 53:2521-2528.
46. Wada A., Yokoo H., Yanagita T., Kobayashi H. New twist on neuronal insulin receptor signaling in health, disease, and therapeutics. J. Pharmacol. Sci. 2005, 99:128-143.
47. Plum L., Belgardt B.F., Brüning J.C. Central insulin action in energy and glucose homeostasis. J. Clin. Invest. 2006, 116:1761-1766.
48. Pocai A., Lam T.K., Gutierrez-Juarez R., Obici S., Schwartz G.J., Bryan J., Aguilar-Bryan L., Rossetti L. Hypothalamic K(ATP) channels control hepatic glucose production. Nature 2005, 434:1026-1031.
49. Girard J. The inhibitory effects of insulin on hepatic glucose production are both direct and indirect. Diabetes 2006, 55:S65-S69.
50. Gispen W.H., Biessels G.J. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 2000, 23:542-549.
51. Carvalheira J.B.C., Ribeiro E.B., Araújo E.P., Guimarães R.B., Telles M.M., Torsoni M., Gontijo J.A., Velloso L.A., Saad M.J. Selective impairment of insulin signalling in the hypothalamus of obese Zucker rats. Diabetologia 2003, 46:1629-1640.
52. Boura-Halfon S., Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E581-E591.
53. Morton G.J., Cummings D.E., Baskin D.G., Barsh G.S., Schwartz M.W. Central nervous system control of food intake and body weight. Nature 2006, 443:289-295.
54. McCall A.L. Cerebral glucose metabolism in diabetes mellitus. Eur. J. Pharmacol. 2004, 490:147-158.
55. Schwartz M.W., Figlewicz D.P., Baskin D.G., Woods S.C., Porte D. Insulin in the brain: a hormonal regulator of energy balance. Endocr. Rev. 1992, 13:387-414.
56. Heidenreich K.A., Brandenburg D. Oligosaccharide heterogeneity of insulin receptors. Comparison of N-linked glycosylation of insulin receptors in adipocytes and brain. Endocrinology 1986, 118:1835-1842.
57. Clarke D.W., Boyd F.T., Kappy M.S., Raizada K. Insulin binds to specific receptors and stimulates 2-deoxy-D-glucose uptake in cultured glial cells from rat brain. J. Biol. Chem. 1984, 259:11672-11675.
58. Park C.R. Cognitive effects of insulin in the central nervous system. Neurosci. Biobehav. Rev. 2001, 25:311-323.
59. Huang T.J., Verkhratsky A., Fernyhough P. Insulin enhances mitochondrial inner membrane potential and increases ATP levels through phosphoinositide 3-kinase in adult sensory neurons. Mol. Cell. Neurosci. 2005, 28:42-54.
60. Hoyer S., Frölich L. Brain function and insulin signal transduction in sporadic Alzheimer's disease. Research Progress in Alzheimer's Disease and Dementia 2006, 23-46. Nova Science, New York, NY, USA. M. Sich (Ed.).
61. Zhao W., Chen H., Xu H., Moore E., Meiri N., Quon M.J., Alkon D.L. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J. Biol. Chem. 1999, 274:34893-34902.
62. Vannucci S.J., Koehler-Stec E.M., Li K., Reynolds T.H., Clark R., Simpson I.A. GLUT4 glucose transporter expression in rodent brain: effect of diabetes. Brain Res. 1998, 797:1-11.
63. Craft S., Watson G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004, 3:169-178.
64. Bingham E.M., Hopkins D., Smith D., Pernet A., Hallett W., Reed L., Marsden P.K., Amiel S.A. The role of insulin in human brain glucose metabolism: an 18fluorodeoxyglucose positron emission tomography study. Diabetes 2002, 51:3384-3390.
65. Ghosh A., Yuk Y.C., Mansfield B.C., Chou J.Y. Brain contains a functional glucose-6-phosphatase complex capable of endogenous glucose production. J. Biol. Chem. 2005, 280:11114-11119.
66. Russell J.W., Golovoy D., Vincent A.M., Mahendru P., Olzmann J.A., Mentzer A., Feldman E.L. High glucose induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J. 2002, 16:1738-1748.
67. Duarte A.I., Proença T., Oliveira C.R., Santos M.S., Rego A.C. Insulin restores metabolic function in cultured cortical neurons subjected to oxidative stress. Diabetes 2006, 55:2863-2870.
68. Duarte A.I., Santos P., Oliveira C.R., Santos M.S., Rego A.C. Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3β signaling pathways and changes in protein expression. Biochim. Biophys. Acta 2008, 1783:994-1002.
69. Koo J.R., Vaziri N.D. Effects of diabetes, insulin and antioxidants on NO synthase abundance and NO interaction with reactive oxygen species. Kidney Int. 2003, 63:195-201.
70. Hasselbalch S.G., Knudsen G.M., Videbaek C., Pinborg L.H., Schmidt J.F., Holm S., Paulson O.B. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes 1999, 48:1915-1921.
71. Seaquist E.R., Damberg G.S., Tkac I., Gruetter R. The effect of insulin on in vivo cerebral glucose concentrations and rates of glucose transport/metabolism in humans. Diabetes 2001, 50:2203-2209.
72. Benedict C., Hallschmid M., Hatke A., Schultes B., Fehm H.L., Born J., Kern W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004, 29:1326-1334.
73. Kern W., Peters A., Fruehwald-Schultes B., Deininger E., Born J., Fehm H.L. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 2001, 74:270-280.
74. Duarte A.I., Santos M.S., Seiça R., Oliveira C.R. Oxidative stress affects synaptosomal γ-aminobutyric acid and glutamate transport in diabetic rats: the role of insulin. Diabetes 2004, 53:2110-2116.
75. Duarte A.I., Santos M.S., Seiça R., Oliveira C.R. Insulin affects synaptosomal GABA and glutamate transport under oxidative stress conditions. Brain Res. 2003, 977:23-30.
76. Craft S., Peskind E., Schwartz M.W., Schellenberg G.D., Raskind M., Porte D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998, 50:164-168.
77. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
78. de la Monte S.M., Wands J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimers Dis. 2005, 7:45-61.
79. Gasparini L., Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci. 2003, 26:404-406.
80. Qiu W.Q., Folstein M.F. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging 2006, 27:190-198.
81. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., Peng Y., Cambareri G., Rocher A., Mobbs C.V., Hof P.R., Pasinetti G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004, 18:902-904.
82. Fakhrai-Rad H., Nikoshkov A., Kamel A., Fernstrom M., Zierath J.R., Norgren S., Luthman H., Galli J. Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. Hum. Mol. Genet. 2000, 9:2149-2158.
83. Leal M.C., Fernandez-Gamba A., Morelli L., Castano E.M. Cerebral proteolysis of amiloid-b peptide: relevance of insulin-degrading enzyme in Alzheimer's disease. Medicina (B Aires) 2009, 69:466-472.
84. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
85. Gasparini L., Gouras G.K., Wang R., Gross R.S., Beal M.F., Greengard P., Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signalling. J. Neurosci. 2001, 21:2561-2570.
86. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423:435-439.
87. Kroner Z. The relationship between Alzheimer's disease and diabetes: type 3 diabetes?. Altern. Med. Rev. 2009, 14:373-379.
88. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., Fuino R.L., Kawaguchi K.R., Samoyedny A.J., Wilson R.S., Arvanitakis Z., Schneider J.A., Wolf B.A., Bennett D.A., Trojanowski J.Q., Arnold S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012, 122:1316-1338.
89. Lester-Coll N., Rivera E.J., Soscia S.J., Doiron K., Wands J.R., de la Monte S.M. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J. Alzheimers Dis. 2006, 9:13-33.
90. Cheng C.M., Tseng V., Wang J., Wang D., Matyakhina L., Bondy C.A. Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 2005, 146:5086-5091.
91. Schubert M., Brazil D.P., Burks D.J., Kushner J.A., Ye J., Flint C.L., Farhang-Fallah J., Dikkes P., Warot X.M., Rio C., Corfas G., White M.F. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J. Neurosci. 2003, 23:7084-7092.
92. Schubert M., Gautam D., Surjo D., Ueki K., Baudler S., Schubert D., Kondo T., Alber J., Galldiks N., Kustermann E., Arndt S., Jacobs A.H., Krone W., Kahn C.R., Bruning J.C. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3100-3105.
93. Jolivalt C.G., Lee C.A., Beiswenger K.K., Smith J.L., Orlov M., Torrance M.A., Masliah E. Defective insulin signalling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J. Neurosci. Res. 2008, 86:3265-3274.
94. Jolivalt C.G., Hurford R., Lee C.A., Dumaop W., Rockenstein E., Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp. Neurol. 2010, 223:422-431.
95. Lesort M., Johnson G.V. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience 2000, 99:305-316.
96. Kim B., Backus C., Oh S., Hayes J.M., Feldman E.L. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 2009, 150:5294-5301.
97. Zhao W.Q., Alkon D.L. Role of insulin and insulin receptor in learning and memory. Mol. Cell. Endocrinol. 2001, 177:125-134.
98. Gasparini L., Netzer W.J., Greengard P., Xu H. Does insulin dysfunction play a role in Alzheimer's disease?. Trends Pharmacol. Sci. 2002, 23:288-293.
99. Brussee V., Cunningham F.A., Zochodne D.W. Direct insulin signalling of neurons reverses diabetic neuropathy. Diabetes 2004, 53:1824-1830.
100. Soeda Y., Tsuneki H., Muranaka H., Mori N., Hosoh S., Ichihara Y., Kagawa S., Wang X., Toyooka N., Takamura Y., Uwano T., Nishijo H., Wada T., Sasaoka T. The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in neuroprotection and memory function in mouse brain. Mol. Endocrinol. 2010, 24:1965-1977.
101. van der Heide L.P., Ramakers G.M.J., Smidt M.P. Insulin signaling in the central nervous system: learning to survive. Prog. Neurobiol. 2006, 79:205-221.
102. Ristow M. Neurodegenetive disorders associated with diabetes mellitus. J. Mol. Med. 2004, 82:510-529.
103. Watson G.S., Craft S. Modulation ofmemory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur. J. Pharmacol. 2004, 490:97-113.
104. Kann O., Kovacs R. Mitochondria and neuronal activity. Am. J. Physiol. Cell Physiol. 2007, 292:C641-C657.
105. Scheepers A., Joost H.G., Schurmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. J. Parenter. Enter. Nutr. 2004, 28:364-371.
106. Zhao W.Q., Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim. Biophys. Acta 2009, 1792:482-496.
107. Baker L.D., Cross D.J., Minoshima S., Belongia D., Watson G.S., Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 2011, 68:51-57.
108. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
109. Moreira P.I. Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J. Alzheimers Dis. 2012, 30:S199-S215.
110. Schmeichel A.M., Schmelzer J.D., Low P.A. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003, 52:165-171.
111. Leinninger G.M., Backus C., Sastry A.M., Yi Y.B., Wang C.W., Feldman E.L. Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim, Bax and the fission protein Drp1. Neurobiol. Dis. 2006, 23:11-22.
112. Edwards J.L., Quattrini A., Lentz S.I., Figueroa-Romero C., Cerri F., Backus C., Hong Y., Feldman E.L. Diabetes regulates mitochondrial biogenesis and fission in mouse neurons. Diabetologia 2010, 53:160-169.
113. Sims-Robinson C., Kim B., Rosko A., Feldman E.L. How does diabetes accelerate Alzheimer disease pathology?. Nat. Rev. Neurol. 2010, 6:551-559.
114. Moreira P.I., Santos M.S., Moreno A.M., Seiça R., Oliveira C.R. Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-β exposure. Diabetes 2003, 52:1449-1456.
115. Cardoso S.M., Proença M.T., Santos S., Santana I., Oliveira C.R. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol. Aging 2004, 25:105-110.
116. Dragicevic N., Mamcarz M., Zhu Y., Buzzeo R., Tan J., Arendash G.W., Bradshaw P.C. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J. Alzheimers Dis. 2010, 20(Suppl. 2):S535-S550.
117. Moreira P.I., Rolo A.P., Sena C., Seica R., Oliveira C.R., Santos M.S. Insulin attenuates diabetes-related mitochondrial alterations: a comparative study. Med. Chem. 2006, 2:299-308.
118. Mastrocola R., Restivo F., Vercellinatto I., Danni O., Brignardello E., Aragno M., Boccuzzi G. Oxidative and nitrosative stress in brain mitochondria of diabetic rats. J. Endocrinol. 2005, 187:37-44.
119. Butterfield D.A., Perluigi M., Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur. J. Pharmacol. 2006, 545:39-50.
120. Silva J.P., Kohler M., Graff C., Oldfors A., Magnuson M.A., Berggren P.O., Larsson N.G. Impaired insulin secretion and beta-cell loss in tissue-specific knockout mice with mitochondrial diabetes. Nat. Genet. 2000, 26:336-340.
121. Moreira P.I., Santos M.S., Sena C., Nunes E., Seiça R., Oliveira C.R. CoQ10 therapy attenuates amyloid β-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp. Neurol. 2005, 196:112-119.
122. Moreira P.I., Santos M.S., Sena C., Seiça R., Oliveira C.R. Insulin protects against amyloid β-peptide toxicity in brain mitochondria of diabetic rats. Neurobiol. Dis. 2005, 18:628-637.
123. Correia S., Carvalho C., Santos M.S., Proença T., Nunes E., Duarte A.I., Monteiro P., Seiça R., Oliveira C.R., Moreira P.I. Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes. Med. Chem. 2008, 4:358-364.
124. Santos M.S., Duarte A.I., Matos M.J., Proença T., Seiça R., Oliveira C.R. Synaptosomes isolated from Goto-Kakizaki diabetic rat brain exhibit increased resistance to oxidative stress: role of vitamin E. Life Sci. 2000, 67:3061-3073.
125. Fernyhough P., Roy Chowdhury S.K., Schmidt R.E. Mitochondrial stress and the pathogenesis of diabetic neuropathy. Expert. Rev. Endocrinol. Metab. 2010, 5:39-49.
126. Frisardi V., Solfrizzi V., Seripa D., Capurso C., Santamato A., Sancarlo D., Vendemiale G., Pilotto A., Panza F. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res. Rev. 2010, 9:399-417.
127. Vasquez-Vivar J., Kalyanaraman B., Kennedy M.C. Mitochondrial aconitase is a source of hydroxyl radical. An electron spin resonance investigation. J. Biol. Chem. 2000, 275:14064-14069.
128. Patel M., Day B.J., Crapo J.D., Fridovich I., McNamara J.O. Requirement for superoxide in excitotoxic cell death. Neuron 1996, 16:345-355.
129. Liu H., Wang H., Shenvi S., Hagen T.M., Liu R.M. Glutathione metabolism during aging and in Alzheimer disease. Ann. N. Y. Acad. Sci. 2004, 1019:346-349.
130. Resende R., Moreira P.I., Proença T., Deshpande A., Busciglio J., Pereira C., Oliveira C.R. Brain oxidative stress in a tripletransgenic mouse model of Alzheimer disease. Free Radic. Biol. Med. 2008, 44:2051-2057.
131. Peerapatdit T., Patchanans N., Likidlilid A., Poldee S., Sriratanasathavorn C. Plasma lipid peroxidation and antioxidiant nutrients in type 2 diabetic patients. J. Med. Assoc. Thai. 2006, 89(Suppl. 5):S147-S155.
132. Baldeiras I., Santana I., Proença M.T., Garrucho M.H., Pascoal R., Rodrigues A., Duro D., Oliveira C.R. Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J. Alzheimers Dis. 2008, 15:117-128.
133. Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006, 15:1437-1449.
134. Kowaltowski A.J., Castilho R.F., Vercesi A.E. Mitochondrial permeability transition and oxidative stress. FEBS Lett. 2001, 495:12-15.
135. Vincent A.M., McLean L.L., Backus C., Feldman E.L. Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J. 2005, 19:638-640.
136. Li Z.G., Zhang W., Sima A.A.F. The role of impaired insulin/IGF action in primary diabetic encephalopathy. Brain Res. 2005, 1037:12-24.
137. Correia S., Carvalho C., Santos M.S., Seiça R., Oliveira C.R., Moreira P.I. Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini-Rev. Med. Chem. 2008, 8:1343-1354.
138. Obrosova I.G., Drel V.R., Pacher P., Ilnytska O., Wang Z.Q., Stevens M.J., Yorek M.A. Oxidative nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes 2005, 54:3435-3441.
139. Goh S.Y., Cooper M.E. Clinical review: the role of advanced glycation end products in progression and complications of Diabetes. J. Clin. Endocrinol. Metab. 2008, 93:1143-1152.
140. Carvalho C., Correia S.C., Santos R.X., Cardoso S., Moreira P.I., Clark T.A., Zhu X., Smith M.A., Perry G. Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia. J. Bioenerg. Biomembr. 2009, 41:433-440.
141. Girones X., Guimera A., Cruz-Sanchez C.Z., Ortega A., Sasaki N., Makita Z., Lafuente J.V., Kalaria R., Cruz-Sanchez F.F. N- epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease. Free Radic. Biol. Med. 2004, 36:1241-1247.
142. Gasser A., Forbes J.M. Advanced glycation: implications in tissue damage and disease. Protein Pept. Lett. 2008, 15:385-391.
143. Engelsen B., Fonnum F. Effects of hypoglycemia on the transmitter pool and the metabolic pool of glutamate in rat brain. Neurosci. Lett. 1983, 42:317-322.
144. 15N]glutamate. J. Neurochem. 1988, 51:892-902.
145. Waagepetersen H.S., Bakken I.J., Larsson O.M., Sonnewald U., Schousboe A. Comparison of lactate and glucose metabolism in cultured neocortical neurons and astrocytes using 13C-NMR spectroscopy. Dev. Neurosci. 1998, 20:310-320.
146. Cardoso S., Carvalho C., Santos R., Correia S., Santos M.S., Seiça R., Oliveira C.R., Moreira P.I. Impact of STZ-induced hyperglycemia and insulin-induced hypoglycemia in plasma amino acids and cortical synaptosomal neurotransmitters. Synapse 2011, 65:457-466.
147. Bak L.K., Schousboe A., Waagepetersen H.S. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J. Neurochem. 2006, 98:641-653.
148. Frigerio F., Casimir M., Carobbio S., Maechler P. Tissue specificity of mitochondrial glutamate pathways and the control of metabolic homeostasis. Biochim. Biophys. Acta 2008, 1777:965-972.
149. Menge B.A., Schrader H., Ritter P.R., Ellrichmann M., Uhl W., Schmidt W.E., Meier J.J. Selective amino acid deficiency in patients with impaired glucose tolerance and type 2 diabetes. Regul. Pept. 2010, 160:75-80.
150. Guyot L.L., Diaz F.G., O'Regan M.H., Song D., Phillis J.W. The effect of topical insulin on the release of excitotoxic and other amino acids from the rat cerebral cortex during streptozotocin-induced hyperglycemic ischemia. Brain Res. 2000, 872:29-36.
151. Phillis J.W., Song D., O'Regan M.H. Effect of hyperglycemia on extracellular levels of amino acids and free fatty acids in the ischemic/reperfused rat cerebral cortex. Brain Res. 1999, 837:177-183.
152. Guyot L.L., Diaz F.G., O'Regan M.H., Song D., Phillis J.W. Topical insulin and accumulation of excitotoxic and other amino acids in ischemic rat cerebral cortex. Exp. Biol. Med. 2000, 224:28-31.
153. Biessels G.J., Van der Heide L.P., Kamal A., Bleys R.L.A.W., Gispen W.H. Ageing and diabetes: implications for brain function. Eur. J. Pharmacol. 2002, 441:1-14.
154. Vilchis C., Salceda R. Effect of diabetes on levels and uptake of putative amino acid neurotransmitters in rat retina and retinal pigment epithelium. Neurochem. Res. 1996, 21:1167-1171.
155. Beauquis J., Saravia F., Coulaud J., Roig P., Dardenne M., Homo-Delarche F., De Nicola A. Prominently decreased hippocampal neurogenesis in a spontaneous model of type 1 diabetes, the nonobese diabetic mouse. Exp. Neurol. 2008, 210:359-367.
156. Stranahan A.M., Arumugam T.V., Cutler R.G., Lee K., Egan J.M., Mattson M.P. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 2008, 11:309-317.
157. Zhang W.J., Tan Y.F., Yue J.T., Vranic M., Wojtowicz J.M. Impairment of hippocampal neurogenesis in streptozotocin-treated diabetic rats. Acta Neurol. Scand. 2008, 117:205-210.
158. Lang B.T., Yan Y., Dempsey R.J., Vemuganti R. Impaired neurogenesis in adult type-2 diabetic rats. Brain Res. 2009, 3:25-33.
159. Lindqvist A., Mohapel P., Bouter B., Frielingsdorf H., Pizzo D., Brundin P., Erlanson-Albertsson C. High-fat diet impairs hippocampal neurogenesis in male rats. Eur. J. Neurol. 2006, 13:1385-1388.
160. Hamilton A., Patterson S., Porter D., Gault V.A., Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 2011, 89:481-489.
161. Wiltrout C., Lang B., Yan Y., Dempsey R.J., Vemuganti R. Repairing brain after stroke: a review on post-ischemic neurogenesis. Neurochem. Int. 2007, 50:1028-1041.
162. Das S., Basu A. Inflammation: a new candidate in modulating adult neurogenesis. J. Neurosci. Res. 2008, 86:1199-1208.
163. Ekdahl C.T., Kokaia Z., Lindvall O. Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 2008, 10.1016/j.neuroscience.2008.06.052.
164. MacLullich A.M.J., Seckl J.R. Diabetes and cognitive decline: are steroids the missing link?. Cell Metab. 2008, 7:286-287.
165. Messier C. Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging. Neurobiol. Aging 2005, 26:S26-S30.
166. Oitzl M.S., Fluttert M., Sutanto W., de Kloet E.R. Continuous blockade of brain glucocorticoid receptors facilitates spatial learning and memory in rats. Eur. J. Neurosci. 1998, 10:3759-3766.
167. Kodl C.T., Seaquist E.R. Cognitive dysfunction and diabetes mellitus. Endocr. Rev. 2008, 29:494-511.
168. Johnson-Farley N.N., Travkina T., Cowen D.S. Cumulative activation of Akt and consequent inhibition of glycogen synthase kinase-3 by brain-derived neurotrophic factor and insulin-like growth factor-1 in cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 2006, 316:1062-1069.
169. Singh P., Jain A., Kaur G. Impact of hypoglycaemia and diabetes on CNS: correlation of mitochondrial oxidative stress with DNA damage. Mol. Cell. Biochem. 2004, 260:153-159.
170. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). J. Am. Med. Assoc. 1999, 281:2005-2012.
171. Auer R.N. Hypoglycemic brain damage. Metab. Brain Dis. 2004, 19:169-175.
172. Suh S.W., Hamby A.M., Swanson R.A. Hypoglycemia, brain energetics, and hypoglycemic neuronal death. Glia 2007, 55:1280-1286.
173. Cardoso S., Santos M.S., Seiça R., Moreira P.I. Cortical and hippocampal mitochondria bioenergetics and oxidative status during hyperglycemia and/or insulin-induced hypoglycemia. Biochim. Biophys. Acta 2010, 1802:942-951.
174. McGowan J.E., Zanelli S.A., Haynes-Laing A.G., Mishra O.P., Delivoria-Papadopoulos M. Modification of glutamate binding sites in newborn brain during hypoglycemia. Brain Res. 2002, 927:80-86.
175. Battezzati A., Benedini S., Fattorini A., Piceni Sereni L., Luzi L. Effect of hypoglycemia on amino acid and protein metabolism in healthy humans. Diabetes 2000, 49:1543-1551.
176. Battezzati A., Benedini S., Sereni L.P., DeTaddeo F., Maffi P., Secchi A., Luzi L. Protein and glutamine kinetics during counter-regulatory failure in type 1 diabetes. Nutr. Metab. Cardiovasc. Dis. 2009, 19:352-357.
177. Palmeira C.M., Santos M.S., Carvalho A.P., Oliveira C.R. Membrane lipid peroxidation induces changes in aminobutyric acid transport and calcium uptake by synaptosomes. Brain Res. 1993, 609:117-123.
178. Sah R., Schwartz-Bloom R.D. Optical imaging reveals elevated intracellular chloride in hippocampal pyramidal neurons after oxidative stress. J. Neurosci. 1999, 19:9209-9217.
179. Saransaari P., Oja S.S. Alanine release from the adult and developing hippocampus is enhanced by ionotropic glutamate receptor agonists and cell-damaging conditions. Neurochem. Res. 1999, 24:407-414.
180. Chen S., Liu A.R., An F.M., Yao W.B., Gao X.D. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease byexendin-4. Age (Dordr) 2012, 34:1211-1224. (PMID: 21901364).
181. Alexander G.C., Sehgal N.L., Moloney R.M., Stafford R.S. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch. Intern. Med. 2008, 168:2088-2094.
182. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., Zinman B. for the American Diabetes Association; European Association for the Study of Diabetes, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
183. Rodbard H.W., Jellinger P.S., Davidson J.A., Einhorn D., Garber A.J., Grunberger G., Handelsman Y., Horton E.S., Lebovitz H., Levy P., Moghissi E.S., Schwartz S.S. AACE/ACE consensus statement: statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract. 2009, 15:540-559.
184. Cimini A., Cerù M.P. Emerging roles of peroxisome proliferator-activated receptors (PPARs) in the regulation of neural stem cells proliferation and differentiation. Stem Cell Rev. 2008, 4:293-303.
185. Tureyen K., Kapadia R., Bowen K.K., Satriotomo I., Liang J., Feinstein D.L., Vemuganti R. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J. Neurochem. 2007, 101:41-56.
186. Pedersen W.A., McMillan P.J., Kulstad J.J., Leverenz J.B., Craft S., Haynatzki G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 2006, 199:265-273.
187. Buse J. Combining insulin and oral agents. Am. J. Med. 2000, 108:23-32.
188. Hsueh W.A., Moore L.M., Bryer-Ash M. Pathophysiology of type 2 diabetes: a quartet of abnormalities. Handbooks in Health Care, Newtown, Pa, USA 2004, 5-19. W.A. Hsueh, L.M. Moore, M. Bryer-Ash (Eds.).
189. Campbell R.K., White J.R. More choices than ever before: emerging therapies for type 2 diabetes. Diabetes Educ. 2008, 34:518-534.
190. Elrick H., Stimmler L., Hlad C.J., Arai Y. Plasma insulin response to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab. 1964, 24:1076-1082.
191. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
192. Vilsbøll T., Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004, 47:357-366.
193. Toft-Nielsen M.B., Damholt M.B., Madsbad S., Hilsted L.M., Hughes T.E., Michelsen B.K., Holst J.J. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. 2001, 86:3717-3723.
194. Toft-Nielsen M.B., Madsbad S., Holst J.J. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J. Clin. Endocrinol. 2001, 86:3853-3860.
195. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
196. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase-IV. Endocrinology 1995, 136:3585-3596.
197. Ahrén B. DPP-4 inhibitors. Best Pract. Res. Clin. Endocrinol. Metab. 2007, 21:517-533.
198. Morimoto C., Schlossman S.F. The structure and function of CD26 in the T-cell immune response. Immunol. Rev. 1998, 161:55-70.
199. Nauck M.A., Vilsbøll T., Gallwitz B., Garber A., Madsbad S. Incretin-based therapies. Viewpoints on the way to consensus. Diabetes Care 2009, 32:S223-S231.
200. Drucker D.J., Sherman S.I., Gorelick F.S., Bergenstal R.M., Sherwin R.S., Buse J.B. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010, 33:428-433.
201. Lamont B.J., Drucker D.J. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 2008, 57:190-198.
202. Gallwitz B. Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs 2011, 71:1675-1688.
203. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5:262-269.
204. DeFronzo R.A., Okerson T., Viswanathan P., Guan X., Holcombe J.H., MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr. Med. Res. Opin. 2008, 24:2943-2952.
205. Bergenstal R.M., Wysham C., Macconell L., Malloy J., Walsh B., Yan P., Wilhelm K., Malone J., Porter L.E., DURATION-2 Study Group Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376:431-439.
206. Pratley R.E., Nauck M., Bailey T., Montanya E., Cuddihy R., Filetti S., Thomsen A.B., Søndergaard R.E., Davies M., 1860-LIRA-DPP-4 Study Group Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycemic control with metformin: a 26-week, randomized, parallelgroup, open-label trial. Lancet 2010, 375:1447-1456.
207. Alvarez E., Martínez M.D., Roncero I., Chowen J.A., García-Cuartero B., Gispert J.D., Sanz C., Vázquez P., Maldonado A., de Cáceres J., Desco M., Pozo M.A., Blázquez E. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J. Neurochem. 2005, 92:798-806.
208. Körner M., Stöckli M., Waser B., Reubi J.C. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nucl. Med. 2007, 48:736-743.
209. Hamilton A., Hölscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009, 20:1161-1166.
210. Li Y., Chigurupati S., Holloway H.W., Mughal M., Tweedie D., Bruestle D.A., Mattson M.P., Wang Y., Harvey B.K., Ray B., Lahiri D.K., Greig N.H. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One 2012, 7:e32008-E32021.
211. Holst J.J., Vilsbøll T., Deacon C.F. The incretin system and its role in type 2 diabetes mellitus. Mol. Cell. Endocrinol. 2009, 297:127-136.
212. Orskov C., Jeppesen J., Madsbad S., Holst J.J. Proglucagon products in plasma of non insulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J. Clin. Invest. 1991, 87:415-423.
213. Gutniak M., Orskov C., Holst J.J., Ahrén B., Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 1992, 336:1316-1322.
214. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
215. Rask E., Olsson T., Söderberg S., Johnson O., Seckl J., Holst J.J., Ahrén B. Northern Sweden Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA), Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001, 24:1640-1645.
216. Rask E., Olsson T., Söderberg S., Holst J.J., Tura A., Pacini G., Ahrén B. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism 2004, 53:624-631.
217. Muscelli E., Mari A., Casolaro A., Camastra S., Seghieri G., Gastaldelli A., Holst J.J., Ferrannini E. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008, 57:1340-1348.
218. Herzberg-Schäfer S., Heni M., Stefan N., Häring H.U., Fritsche A. Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia. Diabetes Obes. Metab. 2012, 14:85-90.
219. Mannucci E., Ognibene A., Cremasco F., Bardini G., Mencucci A., Pierazzuoli E., Ciani S., Fanelli A., Messeri G., Rotella C.M. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet. Med. 2000, 17:713-719.
220. Zhang F., Tang X., Cao H., Lü Q., Li N., Liu Y., Zhang X., Zhang Y., Cao M., Wan J., An Z., Tong N. Impaired secretion of total glucagon-like peptide 1 in people with impaired fastingglucose combined impaired glucose tolerance. Int. J. Med. Sci. 2012, 9:574-581.
221. Vilsbøll T., Krarup T., Deacon C.F., Madsbad S., Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
222. Lee S., Yabe D., Nohtomi K., Takada M., Morita R., Seino Y., Hirano T. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr. J. 2010, 7:119-126.
223. Vollmer K., Holst J.J., Baller B., Ellrichmann M., Nauck M.A., Schmidt W.E., Meier J.J. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008, 57:678-687.
224. Nauck A.M., Vardarli I., Deacon F.C., Holst J.J., Meier J.J. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. Diabetologia 2011, 54:10-18.
225. Kozawa J., Okita K., Imagawa A., Iwahashi H., Holst J.J., Yamagata K., Shimomura I. Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. Biochem. Biophys. Res. Commun. 2010, 393:410-413.
226. Rodriquez de Fonseca F., Navarro M., Alvarez E., Roncero I., Chowen J.A., Maestre O., Gómez R., Muñoz R.M., Eng J., Blázquez E. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 2000, 49:709-717.
227. Gedulin B., Tatarkiewicz K., Smith P., Wilson J., Bhole D., Kendall D., Hargrove D., Parkes D. Contrasting actions of sitagliptin and exenatide on food intake, body weight, glucose stimulated insulin secretion and gastric emptying in rodents (abstract no. 0576). Diabetologia 2007, 50(Suppl. 1):S239.
228. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 2002, 18:7-14.
229. Gil-Lozano M., Pérez-Tilve D., Alvarez-Crespo M., Martís A., Fernandez A.M., Catalina P.A., Gonzalez-Matias L.C., Mallo F. GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans. Endocrinology 2010, 151:2629-2640.
230. Pérez-Tilve D., González-Matías L., Alvarez-Crespo M., Leiras R., Tovar S., Diéguez C., Mallo F. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 2007, 56:143-151.
231. Knauf C., Cani P.D., Kim D.H., Iglesias M.A., Chabo C., Waget A., Colom A., Rastrelli S., Delzenne N.M., Drucker D.J., Seeley R.J., Burcelin R. Role of central nervous system glucagon-like peptide-1 receptors in enteric glucose sensing. Diabetes 2008, 57:2603-2612.
232. Hölscher C. The role of GLP-1 in neuronal activity and neurodegeneration. Vitam. Horm. 2010, 84:331-354.
233. Holst J.J., Burcelin R., Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr. Med. Res. Opin. 2011, 27:547-558.
234. Isacson R., Nielsen E., Dannaeus K., Bertilsson G., Patrone C., Zachrisson O., Wikström L. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol. 2011, 650:249-255.
235. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 2003, 9:1173-1179.
236. Abbas T., Faivre E., Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res. 2009, 205:265-271.
237. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 2003, 27:313-318.
238. Banks W.A., During M.J., Niehoff M.L. Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J. Pharmacol. Exp. Ther. 2004, 309:469-475.
239. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., Greig N.H. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 2002, 300:958-966.
240. Li Y., Perry T., Kindy M.S., Harvey B.K., Tweedie D., Holloway H.W., Powers K., Shen H., Egan J.M., Sambamurti K., Brossi A., Lahiri D.K., Mattson M.P., Hoffer B.J., Wang Y., Greig N.H. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1285-1290.
241. Li Y., Tweedie D., Mattson M.P., Holloway H.W., Greig N.H. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 2010, 113:1621-1631.
242. Iwai T., Ito S., Tanimitsu K., Udagawa S., Oka J. Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes. Neurosci. Res. 2006, 55:352-360.
243. Kim S., Moon M., Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol. 2009, 202:431-439.
244. Hattori Y., Jojima T., Tomizawa A., Satoh H., Hattori S., Kasai K., Hayashi T. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010, 53:2256-2266.
245. Perry T., Greig N.H. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2005, 2:377-385.
246. Martin B., Golden E., Carlson O.D., Pistell P., Zhou J., Kim W., Frank B.P., Thomas S., Chadwick W.A., Greig N.H., Bates G.P., Sathasivam K., Bernier M., Maudsley S., Mattson M.P., Egan J.M. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 2009, 58:318-328.
247. Bradley D.P., Kulstad R., Schoeller D.A. Exenatide and weight loss. Nutrition 2010, 26:243-249.
248. Tong J., Sandoval D.A. Is the GLP-1 system a viable therapeutic target for weight reduction?. Rev. Endocrinol. Metab. Disord. 2011, 12:187-195.
249. Good D.J. Extending the reach of exendin-4: new pathways in the control of body weight and glucose homeostasis. Endocrinology 2012, 153:2051-2053.
250. Cummings D., Overduin J. Gastrointestinal regulation of food intake. J. Clin. Invest. 2007, 117:13-23.
251. Dalvi P.S., Nazarians-Armavil A., Purser M.J., Belsham D.D. Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding associated neuropeptides in hypothalamic neurons in vivo and in vitro. Endocrinology 2012, 153:2208-2222.
252. Pannacciulli N., Bunt J.C., Koska J., Bogardus C., Krakoff J. Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am. J. Clin. Nutr. 2006, 84:556-560.
253. Shalev A., Holst J.J., Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur. J. Clin. Investig. 1997, 27:10-16.
254. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., Hollenberg A.N., Baggio L., Saper C.B., Drucker D.J., Elmquist J.K. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 2002, 110:43-52.
255. Nogueiras R., Perez-Tilve D., Veyrat-Durebex C., Morgan D.A., Varela L., Haynes W.G., Patterson J.T., Disse E., Pfluger P.T., López M., Woods S.C., DiMarchi R., Diéguez C., Rahmouni K., Rohner-Jeanrenaud F., Tschöp M.H. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J. Neurosci. 2009, 29:5916-5925.
256. Perley M.J., Kipnis D.M. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J. Clin. Invest. 1967, 46:1954-1962.
257. Young A.A., Gedulin B.R., Bhavsar S., Bodkin N., Jodka C., Hansen B., Denaro M. Glucose-lowering and insulinsensitizing actions of exendin-4: studies in obese diabetic. Diabetes 1999, 48:1026-1034.
258. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J. Biol. Chem. 1992, 267:7402-7405.
259. Fortin J.P., Schroeder J.C., Zhu Y., Beinborn M., Kopin A.S. Pharmacological characterization of human incretin receptor missense variants. J. Pharmacol. Exp. Ther. 2010, 332:274-280.
260. Hayes M.R., Leichner T.M., Zhao S., Lee G.S., Chowansky A., Zimmer D., De Jonghe B.C., Kanoski S.E., Grill H.J., Bence K.K. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metab. 2011, 13:320-330.
261. Kim B.J., Zhou J., Martin B., Carlson O.D., Maudsley S., Greig N.H., Mattson M.P., Ladenheim E.E., Wustner J., Turner A., Sadeghi H., Egan J.M. Transferrin fusion technology: a novel approach to prolonging biological half-life ofinsulinotropic peptides. J. Pharmacol. Exp. Ther. 2010, 334:682-692.
262. Al-Barazanji K.A., Arch J.R., Buckingham R.E., Tadayyon M. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes. Res. 2000, 8:317-323.
263. Pritchett C.E., Hajnal A. Glucagon-like peptide-1 regulation of carbohydrate intake is differentially affected byobesogenic diets. Obesity (Silver Spring) 2012, 20:313-317.
264. Baraboi E.D., St-Pierre D.H., Shooner J., Timofeeva E., Richard D. Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 301:R1011-R1024.
265. Lim J.G., Lee J.J., Park S.H., Park J.H., Kim S.J., Cho H.C., Baek W.K., Kim D.K., Song D.K. Glucagon-like peptide-1 protects NSC-34 motor neurons against glucosamine through Epac-mediated glucose uptake enhancement. Neurosci. Lett. 2010, 479:13-17.
266. Ranganath L.R., Beety J.M., Morgan L.M., Wright J.W., Howland R., Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence?. Gut 1996, 38:916-919.
267. Adam T.C., Westerterp-Plantenga M.S. Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects. Br. J. Nutr. 2005, 93:845-851.
268. Morínigo R., Moizé V., Musri M., Lacy A.M., Navarro S., Marín J.L., Delgado S., Casamitjana R., Vidal J. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J. Clin. Endocrinol. Metab. 2006, 91:1735-1740.
269. Holdstock C., Zethelius B., Sundbom M., Karlsson F.A., Edén Engström B. Postprandial changes in gut regulatory peptides in gastric bypass patients. Int. J. Obes. (Lond.) 2008, 32:1640-1646.
270. Gutzwiller J.P., Göke B., Drewe J., Hildebrand P., Ketterer S., Handschin D., Winterhalder R., Conen D., Beglinger C. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999, 44:81-86.
271. Naslund E., Barkeling B., King N., Gutniak M., Blundell J.E., Holst J.J., Rössner S., Hellström P.M. Energy intake and appetite is suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int. J. Obes. 1999, 3:304-311.
272. Washington M.C., Raboin S.J., Thompson W., Larsen C.J., Sayegh A.I. Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor. Brain Res. 2010, 1344:124-133.
273. Darsalia V., Mansouri S., Ortsäter H., Olverling A., Nozadze N., Kappe C., Iverfeldt K., Tracy L.M., Grankvist N., Sjöholm A., Patrone C. Glucagon-like peptide 1 receptor activation reduces ischaemic brain damage followingstroke in Type 2 diabetic rats. Clin. Sci. (Lond.) 2012, 122:473-483.
274. Bunck M.C., Diamant M., Cornér A., Eliasson B., Malloy J.L., Shaginian R.M., Deng W., Kendall D.M., Taskinen M.R., Smith U., Yki-Järvinen H., Heine R.J. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009, 32:762-768.
275. Kolterman O.G., Kim D.D., Shen L., Ruggles J.A., Nielsen L.L., Fineman M.S., Baron A.D. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am. J. Health Syst. Pharm. 2005, 62:173-181.
276. Teramoto S., Miyamoto N., Yatomi K., Tanaka Y., Oishi H., Arai H., Hattori N., Urabe T. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 2011, 31:1696-1705.
277. Tourrel C., Bailbe D., Lacorne M., Meile M.J., Kergoat M., Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002, 51:1443-1452.
278. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., Wintle M.E., Maggs D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3years. Curr. Med. Res. Opin. 2008, 24:275-286.
279. Fan R., Li X., Gu X., Chan J.C., Xu G. Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. Diabetes Obes. Metab. 2010, 12:815-824.
280. Barnett A.H., Burger J., Johns D., Brodows R., Kendall D.M., Roberts A., Trautmann M.E. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin. Ther. 2007, 29:2333-2348.
281. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., Tweedie D., Perry T., Mattson M.P., Kapogiannis D., Sambamurti K., Lahiri D.K., Greig N.H. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:1205-1219.
282. Bertilsson G., Patrone C., Zachrisson O., Andersson A., Dannaeus K., Heidrich J., Kortesmaa J., Mercer A., Nielsen E., Rönnholm H., Wikström L. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 2008, 86:326-338.
283. Harkavyi A., Abuirmeileh A., Lever R., Kingsbury A., Biggs C., Whitton P.S. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation 2008, 5:19.
284. Perry T., Holloway H.W., Weerasuriya A., Mouton P.R., Duffy K., Mattison J.A., Greig N.H. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine induced peripheral sensory neuropathy. Exp. Neurol. 2007, 203:293-301.
285. McClean P.L., Parthsarathy V., Faivre E., Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 2011, 31:6587-6594.
286. Perry T., Haughey N.J., Mattson M.P., Egan J.M., Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 2002, 302:881-888.
287. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 2003, 72:603-612.
288. Calara F., Taylor K., Han J., Zabala E., Carr E.M., Wintle M., Fineman M. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic Exendin-4). Clin. Ther. 2005, 27:210-215.
289. Gault V.A., Porter W.D., Flatt P.R., Holscher C. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int. J. Obes. 2010, 34:1341-1344.
290. Nauck M.A., Duran S., Kim D., Johns D., Northrup J., Festa A., Brodows R., Trautmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267.
291. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., Porter L. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250. for the DURATION-1 Study Group.
292. Delamater A.M. Improving patient adherence. Clin. Diabetes 2006, 24:71-77.
293. Ingersoll K.S., Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of the literature. J. Behav. Med. 2008, 31:213-224.
294. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol. Cell. Endocrinol. 2009, 297:137-140.
295. Arnold S.E., Hyman B.T., Flory J., Damasio A.R., Van Hoesen G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1991, 1:103-116.
296. Han W.N., Hölscher C., Yuan L., Yang W., Wang X.H., Wu M.N., Qi J.S. Liraglutide protects against amyloid-β protein induced impairment of spatial learning andmemory in rats. Neurobiol. Aging 2013, 34:576-588. (Electronic publication ahead of print).
297. Hunter K., Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012, 13:33-38.
298. Brinton R.D., Wang J.M. Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: allopregnanolone as a proof of concept neurogenic agent. Curr. Alzheimer Res. 2006, 3:185-190.
299. Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Muller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., Laferla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13594-13599.
300. Porter D.W., Kerr B.D., Flatt P.R., Holscher C., Gault V.A. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes. Metab. 2010, 12:891-899.
301. Christensen M., Knop F.K., Vilsboll T., Holst J.J. Lixisenatide for type 2 diabetes mellitus. Expert Opin. Investig. Drugs 2011, 20:549-557.
302. Porter W.D., Flatt P.R., Hölscher C., Gault V.A. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice. Int. J. Obes. (Lond.) 2012, ( Jun 5, Electronic publication ahead of print). 10.1038/ijo.2012.91.
303. Kanoski S.E., Fortin S.M., Arnold M., Grill H.J., Hayes M.R. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011, 152:3103-3112.
304. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
305. Vella A., Shah P., Reed A.S., Adkins A.S., Basu R., Rizza R.A. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 2002, 45:1410-1415.